Intensity Therapeutics Inc.
Intensity Therapeutics, Inc. is a phase 2 clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.In 2021 we met with FDA to review our a phase 3 program and protocol for our lead drug INT230-6 to treat soft tissue sarcoma. Intensity leverages its DfuseRx℠ technology platform to create novel, proprietary drugs that, following direct injection into tumors, rapidly disperse throughout a tumor and diffuse therapeutic agents into the cancer cells causing tumor necrosis.The Company was awarded a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Vaccine Branch in 2014 and has on-going phase 2 clinical partnerships with Merck and Bristol-Myers Squibb.
Private: S-1 Filed
IR Website: https://intensitytherapeutics.com/news/
Headquarters: Westport, CT
Content provided by Intensity Therapeutics Inc on 3/2/22.
TALK TO MANAGEMENT
The Intensity Therapeutics management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Intensity Therapeutics, Inc. is a phase 2 clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. In 2021 we met with FDA to review our a phase 3 program and protocol for our lead drug INT230-6 to treat soft tissue sarcoma. Intensity leverages its DfuseRx℠ technology platform to create novel, proprietary drugs that, following direct injection into tumors, rapidly disperse throughout a tumor and diffuse therapeutic agents into the cancer cells causing tumor necrosis. Intensity’s product candidates can induce an adaptive systemic immune response that attacks the injected tumor and also non-injected tumors. The Company was awarded a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Vaccine Branch in 2014 and has on-going phase 2 clinical partnerships with Merck and Bristol-Myers Squibb. For more information, please visit www.intensitytherapeutics.com.
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
Dec 10, 2021
Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December
Nov 30, 2021
Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Nov 13, 2021
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting
Nov 12, 2021
Lewis H. Bender
Chief Executive Officer, President
Lewis H. Bender is our founder and has served as our President and Chief Executive Officer since April 2012. Prior to our founding, Mr. Bender was the CEO of publicly traded (AMEX & OTC) Interleukin Genetics, Inc. from 2008 until 2012. Interleukin was a personalized medicine company. Mr. Bender was successful in raising capital for us via a direct placement with institutional investors and partnered with the insurance industry for development of an IG product. Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc. at the time a publicly traded (Nasdaq) drug delivery company specializing in the development of oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December 2007, Mr. Bender held positions including Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. Mr. Bender has over 26 years of biotech and pharmaceutical executive management experience. He has led development teams taking products from discovery to Phase 3 for compounds using novel drug delivery techniques. Mr. Bender has a both a BS and MS in Chemical Engineering from The Massachusetts Institute of Technology (MIT), an MBA from the University of Pennsylvania’s Wharton School, and an MA in International Studies also from the University of Pennsylvania. He is fluent in French and German.
James M. Ahlers
Chief Financial Officer
James M. Ahlers has served as Chief Financial Officer since January 2022 through a consulting agreement with Mr. Ahlers’ employer, Danforth Advisors LLC, a company that provides strategic and operational finance and accounting services to life science companies. From February 2002 to November 2019 Mr. Ahlers served as Chief Financial Officer of Intarcia Therapeutics, Inc. Mr. Ahlers is an accomplished finance leader with 25 years of experience building life science businesses. During his career, he has managed capital raising transactions, including IPOs, that have raised in excess of $2 billion. In addition, he has developed and implemented international operations and global tax strategies. Mr. Ahlers holds a B.S. in accounting from the University of San Francisco. Mr. Ahlers replaces Greg Wade, who left Danforth at the end of 2021 to pursue a full time position in business development at a third party biotech firm.
Dr. Ian B. Walters
Vice President, Chief Medical Officer
Dr. Ian B. Walters has served as our Vice President and Chief Medical Officer since August 2014. Dr. Walters brings over 15 years of oncology/immunology drug development experience to our team. Dr. Walters has clinical development experience with 30+ compounds, and has been a consultant to biotech, pharma and investment companies specializing in the evaluation, prioritization, and development of innovative technologies in the treatment of severe diseases. He has worked in multiple biotech companies on corporate development, translational medicine, clinical development and medical affairs including BMS, Millennium, PDL and the Rockefeller University. Dr. Walters spent seven years at Bristol-Myers Squibb (BMS), where he led clinical research and matrix development teams. During his tenure there he contributed to the development of multiple immuno-oncology products, Yervoy® (ipilimumab) and Opdivo (nivolumab, an anti-PD-1 drug), as well as the licensing and partnering strategy for other immuno-oncologic agents. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.
Dr. Syed Mahmood
Senior Vice President of Clinical Developement
Dr. Syed Mahmood has served as our Senior Vice President of Clinical Development since September 2020. He is a physician-scientist with over 13 years of experience in the US and Global pharmaceutical/biotechnology industry, in leading strategic, translational medicine, clinical development, medical affairs, and operations teams. Prior to joining Intensity Therapeutics, Dr. Mahmood was the Vice President and Head, Global Medical Affairs, Research and Development at Progenics Pharmaceuticals in New York City. Previously, he has held US and global leadership positions of increasing levels of responsibility at Novartis, GlaxoSmithKline, Daiichi Sankyo, and GE Healthcare. Over the course of his career, he has successfully built and led teams and departments responsible for Phase I to III clinical programs for small molecules, biologics and radiopharmaceuticals across many therapeutic areas, including oncology. He has played critical roles in multiple development programs and launches including Progenics's AZEDRA and PyL, and GSK's/Novartis's Tafinlar, Mekinist, Votrient, Luminespib and Buparlisib programs. Dr. Mahmood received his MD from the George Washington University School of Medicine and Health Sciences, Washington, DC. He completed a medical internship from Aria–Jefferson Health, Philadelphia, PA, and a residency in Nuclear Medicine from Memorial Sloan Kettering Cancer Center, New York, NY. He also served as a PET fellow and an Assistant Professor/Attending Physician in Nuclear Medicine at the Montefiore Medical Center, Bronx, NY, an Attending Physician in Radiology at the University of Pennsylvania, Philadelphia, PA, and an Attending Physician in Jacobi Medical Center- New York City’s Health and Hospitals Corporation Bronx, NY. He is board-certified by the American Board of Nuclear Medicine.
Principle Accounting Officer and Controller
John Wesolowski has served as our Principal Accounting Officer and Controller since March 2017. Prior to joining Intensity Therapeutics, from 1998 to 2016 Mr. Wesolowski was Director of Costing in the Yale University Controller’s office. In that role Mr. Wesolowski conducted financial reporting, property tax management, was responsible for calculations of overhead and benefit rates, and was involved in numerous special projects related to accounting process and controls. Also, at Yale, he was involved in financial reporting and the accounting matters related to clinical trials and other organized research. Prior to joining Yale Mr. Wesolowski was the Vice President and Controller for Automatic Fastener Corporation in Branford, CT from 1988 to 1998. In this role, Mr. Wesolowski oversaw all accounting, purchasing and human resource functions. John also has 5 years of experience in public accounting and auditing from working at KMG Main Hurdman, now KPMG. Mr. Wesolowski received a Bachelor of Science in Finance from The Pennsylvania State University (Penn State at University Park) and an MBA from the University of Connecticut in Management Science. He is a Certified Public Account since 1983.
Vice President, Regulatory Affairs and Quality
Rebecca Drain has served as our Vice President, Regulatory Affairs and Quality since August 2021 and prior to that as our Executive Director of Regulatory Affairs and Quality Assurance since July 2019. Prior to joining Intensity Therapeutics, Ms. Drain has over 25 years of experience with Bristol Myers Squibb, where most recently, between January 2015 and December 2018, she served as Director, Submission Management, Global Regulatory Safety and Biometrics, a position in which she was responsible for global oncology regulatory submissions. Prior to BMS, she was a research scientist with a drug discovery company. Ms. Drain earned a B.S. in Pathobiology from the University of Connecticut.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Intensity Therapeutics Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.